Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous ex vivo activated natural killer cells (NUH Singapore)
- Development stage
- Unknown
- Lead developer
- National University Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This autologous cell therapy consists of natural killer (NK) cells that are harvested from a patient via leukapheresis, expanded and activated *ex vivo*, and subsequently reinfused into the same patient. Developed by the National University Hospital, Singapore, specifically for the treatment of metastatic nasopharyngeal carcinoma (NPC), the therapy aims to leverage the innate anti-tumor activity of NK cells. In clinical practice, these activated NK cells are typically administered alongside low-dose interleukin-2 (IL-2) to enhance their survival and cytotoxic function in the systemic circulation. The treatment was evaluated in a Phase 1 pilot study (NCT00717184) to assess safety and feasibility in patients who had failed prior systemic treatments for metastatic disease.
- Other names
- autologous activated NK cellsex vivo activated NK cellsautologous ex vivo activated natural killer cells
Beyond the preview
Go deeper on autologous ex vivo activated natural killer cells (NUH Singapore).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous ex vivo activated natural killer cells (NUH Singapore).